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Abstract 
Introduction: Biochemical failure in the first 2 years after radical prostatectomy confers an adverse prognosis compared to later 
biochemical relapse. This supplementary analysis of the Irish Clinical Oncology Research Group Trial 97-01 assess if this is also the 
case for patients managed with neo-adjuvant hormonal treatment and radiotherapy. 
Methods: The Irish Clinical Oncology Group initiated a prospective randomised trial (ICORG 97-01) that compared 4 versus 8 
months of neo-adjuvant androgen deprivation therapy (NADT) for patients treated with 3D conformal radiotherapy (RT) for 
prostate cancer. This supplementary study describes a Cox regression analysis of data from 253 participants in that trial. 
Results: In patients with EBF (early biochemical failure) i.e., within 2 years, median survival time after completion of radiotherapy 
is 8.9 years, compared to 12.6 years in patients with LBF (late biochemical failure). Prostate cancer specific mortality risk was 
higher in the EBF cohort (Hazard ration (HR)= 6.75, 95% Confidence Interval (C.I.)= 3.1–14.7, P-value < 0.0001) compared to 
those with LBF. The risk of EBF was higher for patients with stage T2c-T4 disease compared those with stage T1-T2b disease (HR= 
2.93, 95% CI= 1.30–6.58, P-value= 0.009). On multivariate analysis the estimated hazard of risk of EBF increased 1.02 fold for each 
increase of 1ng/mL in initial PSA. In the multi-variate model Gleason score also predicted EBF.
Conclusion: Patients with prostate cancer treated with neo-adjuvant androgen deprivation therapy and radiation therapy that 
develop EBF have a shorter median duration of prostate cancer specific mortality (PCSS) than those with LBF. 
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Introduction 
Androgen deprivation therapy (ADT) combined with external 
beam radiotherapy (RT) improves outcome for patients with 
prostate cancer. Randomised trials of ADT and RT for locally 
advanced prostate cancer include RTOG 85-31, EORTC 22863, 
RTOG 86-10, RTOG 92-02, RTOG 94-13, TROG 96.01, and a study 
from Brigham and Women’s Hospital, Boston [1]. We report an 
unplanned secondary analysis of ICORG 97-01, a randomised 
trial comparing 4 versus 8 months of neo-adjuvant ADT (NADT) 
prior to RT in localised prostate cancer. In a population of 
correlative interest, patients that fail biochemically within 2 
years of a radical prostatectomy have an unfavourable prognosis 
[2]. We examined the hypothesis that this subgroup would 
also have an unfavourable prognosis in patients treated with 
neo-adjuvant hormonal therapy and radiation. The relationship 
between time of biochemical failure (BF) following RT and 
prostate-cancer-specific survival (PCSS) is assessed. Age, initial 
PSA (last PSA pre NADT), Gleason score, T-stage and duration 
of NADT were also assessed for correlation with EBF.  
Methods     
The ICORG 97-01 trial was a randomised phase III clinical trial, 
comparing 4 months versus 8 months (arms 1 and 2 respectively) 
of NADT followed by RT (70Gy). 276 patients with prostatic 
adenocarcinoma were accrued. Patients had localised, node 
negative disease.
  
Eligibility criteria 
Inclusion criteria: PSA >20ng/mL, Gleason score greater or 
equal to 7, or stage T3 or more, Karnofsky performance status 
(KPS) of greater or equal to 60. Exclusion criteria: Previous 
treatment for prostate cancer (other than transurethral 
resection of the prostate), bilateral orchidectomy, prior ADT, 
previous malignancy (other than non-melanoma skin cancer), 
and uncontrolled severe medical illnesses. Evaluation included 
history and physical examination, KPS assessment, complete 
blood count, liver function tests, chest radiograph, bone scan, 
and computed tomography (CT) pelvis to exclude metastasis.
Follow-up
Year 1, monthly. Subsequent follow-up, 3 monthly. Included 
history, rectal examination, PSA, and toxicity assessment. 
Treatment failure was defined as clinical evidence of local or 
distant recurrence or BF. 
Design and procedures
276 patients with adenocarcinoma of the prostate were enrolled 
in a phase III clinical trial comparing 4 versus 8 months of 
Oncology Discovery
ISSN 2052-6199
Kelleher et al. Oncology Discovery 2013, 
http://www.hoajonline.com/journals/pdf/2052-6199-1-2.pdf
2
doi: 10.7243/2052-6199-1-2
neo-adjuvant hormonal therapy followed by radiotherapy. 
All patients were node negative and had no metastases. 
The neo-adjuvant hormonal therapy was the LHRH agonist 
(Triptorelin 3.75mg im once monthly) combined with anti-
androgen therapy (flutamide 250mg po 3 times daily) (Figure 1).
Statistical analysis
The definition of biochemical (PSA) failure in the trial protocol 
was in accordance with the American Society for Therapeutic 
Radiation statement but data were analysed using the 
new definition of BF, defined as PSA >nadir after RT +2ug/L 
measured at least 18 months after completion of RT [3,4,5].
PSA doubling time was calculated as; PSADT (months) = ln 
2 × [(month 2 – month 1) / (ln PSA2 - ln PSA1)] [6]. Cause of 
death was taken from the death certificate and by a review 
of patient records if the death certificate was inadequate. To 
record death as caused by prostate cancer, there had to be 
documented metastatic prostate cancer or hormone-refractory 
prostate cancer (HRPC) and evidence that the PSA level was 
increasing at the time of the last follow-up visit despite the 
use of second-line hormones before death.
Time to PCSS was calculated from the date enrolled or 
date of consent (whichever was earliest) to the date of death 
if the death was disease related, or date of last contact. The 
Kaplan-Meier method was used to estimate survival times [7].
Cox regression analysis was used to determine univariate 
predictors of PCSS and time to EBF. Variables with a P ≤ 0.10 
were included in the multivariate models. The proportional 
hazards assumption of the Cox model was tested through the 
graphical examination of the log-log plots of the variables 
used in the model. These plots formed approximate parallel 
straight lines as required. All statistical tests were two-sided 
and assessed for significance at the 0.05 level, except in 
analyses in which a Bonferroni adjustment for multiple 
comparisons was applied, in which case the significance 
level was 0.05, divided by the number of comparisons. All 
Figure 1. Randomised trial ICORG 97-01 (1997-2001). 4-month neo-adjuvant hormone therapy versus 
8 months prior to radiation. N0 M0.
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n=253 Biochemical Failure (BF)
BF
n=110
EBF
n=45
LBF 
N=65
Age (years)
  Mean
  Median
66.2
67·3
66.1
67·4
065.4
66·5
066.5
67·8
PSA 
  Mean ug/L    
  Median ug/L
  Range ug/L   
                       >20
22.7
14.6
  0.6-262.8
95 (37%)
28.5
18.3
  1.7-262.8
48 (44%)
39.7
21.9
  5.7-262.8
27 (60%)
20.7
14.2
  1.7-88.3
21 (32%)
Gleason Score
    < 7
    = 7
    > 7
105 (42%) 
115 (45%)
  33 (13%)
32 (29%) 
52 (47%)
26 (24%)
  9 (20%) 
24 (53%)
12 (27%)
23 (35%) 
28 (43%)
14 (22%)
T Stage
    T1
    T2
    T3
    T4
  27 (11%) 
  73 (29%)
136 (54%)
  17 (7%)
  9 (8%) 
24 (22%)
67 (61%)
10 (9%)
  0 (0%) 
  7 (16%)
33 (73%)
  5 (11%)
  9 (14%) 
17 (26%)
34 (52%)
  5 (8%)
T Stage Grp
    T1 -T2b
    T2c-T4
  97 (38%)
156 (62%)
33 (30%)
77 (70%)
  7 (16%)
38 (84%)
26 (40%)
39 (60%)
Salvage hormone therapy 102 (40%) 99 (90) 43 (96%) 56 (86%)
Median months from BF to 
SHT (range) (n= 99)
  - 3.4 (0-35) 3.2 (0-35) 4.1(0-33)
PSADT Median (range) 
months (n= 98)
- 2.1 (0-74) 1.5 (0-62) 4.4(0-74)
PSA nadir on SHT ng/mL 
Median (range) n= 97
- 0.04(0-86) 0.1 (0-58) 0.04(0-86)
HRPC (n= 98) - 40 (41%) 28 (65%) 12 (22%)
Metastatic disease 48 (19%) 46 (42%) 30 (67%) 16 (25%)
Median months from BF to 
metastases (range) (n=46)
- 13.2 (0-98) 18.9(0-98) 8.2(0-78)
Median months from BF to 
death (range) (n=48)
  - 43 (0-121) 49 (2-121) 42 (0-82)
Median months from  
metastases to death (range) 
(n=38)
  - 21.2 (0-96) 25.7 (2-96) 15.1 (0-64)
Disease specific death 38 (15%) 36 (33%) 26 (58%) 10 (15%)
Table 1. Patient characteristics and clinical outcomes in the ICORG 
97-01 study. 
Data are for number of patients unless otherwise specified.
Abbreviations: PSA= prostate-specific antigen; SHT= salvage 
hormone therapy; PSADT= PSA doubling time (from BF to 
initiation of salvage hormones); HRPC= hormone-refractory 
prostate cancer (progression on SHT as evidenced by three 
consecutive PSA increases taken at least one week apart or findings 
on physical examination or imaging studies).
statistical analyses were performed using SPSS version 18 
(SPSS, Inc., Chicago, IL, USA).
Results
The median follow-up, from consent to last contact, for all 
living patients was 111 months (range 54–158). The median 
follow-up, from the end of RT to last PSA test, for patients 
living free from BF was 96 months (range 57–141). 
Median initial PSA was higher in patients with EBF, 22 ng/
ml compared with 14ng/ml in those with LBF. None of those 
with T1 disease had EBF. Twenty-nine percent of those with 
T2 disease had EBF.
In addition, 58% of those with PCSM had EBF compared 
to 15% of those with LBF. Salvage hormone treatment was 
Failure
BF Total
No Yes
Local or distant progression No 139 (97%) 0 139 (55%)
Yes 4 (3%) 110 114 (45%)
Total Total  143 110 253
Table 2. Local or distant progression by biochemical failure 
(BF) (n= 253).
received by 96% of those with EBF and by 86% of patients 
with LBF. The median time to salvage hormone therapy was 
3 months for those with EBF and 4 months for those with LBF 
(Table 1) (Table 2). 30% (77 of 253) of the patients died (28/77 
had been diagnosed with a second primary cancer). 38 of the 
77 had known metastatic disease and death was attributed 
to prostate cancer in all except one patient. Four patients 
of the 37 with metastatic disease whose death was caused 
by prostate cancer did not have HRPC and 2 did not have 
salvage hormones. One patient whose death was caused 
by prostate cancer had HRPC but no distant metastases 
(Table 3) (Figure 2).
PCSS curves by EBF/ LBF are curtailed at 120 months when 
7 and 28 cases were remaining for EBF and LFB respectively 
(Figure 2). Patients with EBF had a median survival time of 
107 months compared to 151 months for those with LBF.
Using a Cox proportional hazards models, risk factors for 
EBF were evaluated as potential prognostic indicators by 
univariate analyses. We found initial PSA group, T-stage 
group and Gleason score group to be predictors of EBF, 
whereas age and arm were not predictive of EBF (Table 4). 
In the multivariate model, after adjustment for the other 
variables, initial PSA, T-Stage group and Gleason score group 
remained as independent predictors for EBF (Table 4). The 
hazard (risk of EBF) is higher and thus the prognosis worse, 
for subjects with higher values of initial PSA (HR= 1.019, 95% 
CI= 1.01–1.02, P-value < 0.0001). The estimated hazard or risk 
of EBF increases by 1.02 times for each increase of 1ng/mL in 
PSA, after adjustment for the effects of T-stage and Gleason 
score (e.g. there would be an estimated 10 fold increase in 
hazard for a patient with a PSA of 21ng/mL compared to 
a patient with a PSA of 11ng/mL). The hazard (risk of EBF) 
is higher and thus the prognosis worse, for subjects with 
T2c–T4 disease (HR= 4.38, 95% CI= 1.90–10.06, p= 0.001). 
Compared to those with T1-T2b, patients with T2c–T4 had 
over 4 times the risk of EBF, after adjustment for initial PSA 
and Gleason score.  The hazard (risk of EBF) is higher and 
thus the prognosis worse, for subjects with Gleason score 
≥ 7. Compared to those with Gleason score <7, patients 
with Gleason score >7 had 4.55 times the risk of EBF, after 
adjustment for initial PSA group and T-Stage group.
Discussion
This analysis of the ICORG 97-01 trial assesses the clinical 
significance of biochemical failure in the first 2 years post 
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Prostate Cancer Specific Mortality Total deaths
Progression/ Failure SHT HRPC
PSA Local Distant Yes No Yes No
Prostate cancer death (%) 34 (77%) 9 (90%) 37 (97%) 36 (77%) 2 (7%) 34 (100%) 4 (9%) 38 (49)
Death from other cause (%) 10 (23%) 1 (10%) 1 (3%) 11 (23%) 28 (93%) 0 39 (91%) 39 (51)
Total - 10 38 47 30 34 43 77
Table 3. Cause of death.
SHT= salvage hormone therapy
Figure 2. Prostate cancer specific survival by early and late 
biochemical failure (n=110).
Covariate Reference 
category
Univariate analysis Multivariate analysis – final 
step
HR 95% CI p HR 95% CI p
Age - 0.98 0.93–1.03 0.353 - - -
Initial PSA - 1.02 1.01–1.02 <0.0001 1.019 1.01–1.02 <0.0001
T-Stage 
T2c–T4
T-Stage 
T1-T2b
3.66 1.63–8.20 0.002 4.38 1.90–10.06 0.001
Gleason 
score
  = 7
  > 7
GS < 7
-
-
-
2.74
4.84
-
1.27–5.89
2.04–11.5
0.002
0.010
<0.0001
-
4.70
4.55
-
2.1-10
1.9-11
<0.0001
<0.0001
0.001
4 mths 
Hormones
8 mths 0.94 0.52–1.68 0.831 - - -
Table 4. Cox Regression Analysis of Early Biochemical Failure 
(n= 253).
HR, hazard ratio or relative risk; CI, confidence interval; PSA, 
prostate-specific antigen.
completion of radiotherapy. In patients with EBF, median survival 
time from the time of randomization was 107 months compared 
to 151 months for those with LBF. The current literature on use 
of EBF as a surrogate of disease specific mortality is summarized 
in (Table 5) with variation in study design and treatment 
administered as well as historic variation in the definition of 
biochemical failure used. The results from this supplementary 
analysis of the ICORG 97-01 trial and other similar trials of 
radiotherapy with neo-adjuvant hormones could benefit from 
a succeeding inter-study comparator review with respect to 
the clinical significance of biochemical failure in the first 
2 years. Study design variations and lack of individualized 
data would demand an international collaborative effort to 
perform a meaningful meta-analysis. The results however 
would be of great practical interest to patients and physicians 
confronted with the problem of early biochemical relapse.
Previous studies have found that rapid PSA increases, or 
short post treatment PSA doubling times, after local therapy 
are associated with the development of metastatic disease 
and PCSM [12,13-17]. D’Amico et al., in a retrospective analysis 
demonstrated that a short PSA doubling time of less than 
3 months meets statistical criteria for being a surrogate 
endpoint for PCSS. However, metrics such as PSA doubling 
time and PSA velocity can be confounded by the methods 
used and frequency of PSA measurements. 
Furthermore, de Crevoisier et al., reported that a PSA 
decline 6 weeks after the start of EBRT when used as 
monotherapy and 3 months after the start of ADT in 
patients treated with combined ADT and EBRT is predictive 
of progression and survival [18]. Patients with a T stage 
T2c-4 compared to T1-2B were 4 times more likely to have 
EBF. We report an association between EBF and death from 
prostate cancer. While this association is not unexpected, it’s 
quantification is nonetheless important. This observation 
is consistent with The Transman study TROG 96.01 [19,20]. 
Our study gives clinicians further insight into the natural 
history of biochemically recurrent prostate cancer after RT 
and NADT. 
It had previously been established that the natural history 
of prostate cancer relapsing post radical prostatectomy is 
that the median interval from biochemical relapse to the 
identification of metastasis is 8 years and the median time 
from metastatic disease to death is 5 years [21]. The ICORG 
study by comparison has shorter intervals. The ‘Pound study’, 
in which 44.7% of patients had early biochemical failure, found 
that the time to biochemical relapse was predictive of the 
probability of and time to development of metastatic disease 
(p< .001). It would appear from the ICORG 97-01 study that 
EBF identifies an important subgroup with a more aggressive 
natural history and short survival. In patients treated with 
neo-adjuvant androgen deprivation and radiation EBF had a 
median PCSS time of 8.9 years. Those experiencing LBF had 
a PCSS time of 12.6 years. Therefore EBF defines a high-risk 
cohort for PCSM. 
Predictors of biochemical recurrence are well established 
and we sought to establish the association of some of the 
Time since randomisation (months)
Cu
m
 S
ur
vi
va
l
Late Biochemical Failure
LBF-censored
EBF-censored
Early Biochemical Failure 
0.00
0.0
0.2
0.4
0.6
0.8
1.0
24.00 48.00 72.00 96.00 120.00
Survival Functions
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Clinical study Number of patients Nature of study Early biochemical failure Main study findings Time to biochemical progression
Pound et al.  1999 
Johns Hopkins
1997 Retrospective review of 
surgical series
136/304 (44.7% of patients 
with BF)
Median time to metastasis 
from time of PSA eleva-
tion= 8 years.
Median time to death from 
metastasis= 5 years
Time to biochemical progression 
was predictive of probability and 
time to development of metastatic 
disease (P<.001)
Freedland et al. 2005 
Johns Hopkins
379 Retrospective study to de-
fine risk factors for prostate 
cancer specific death post 
radical prostatectomy
In this study segregation at 
3 years after surgery to BF 
found to be the best risk 
stratification
PSADT, Gleason score and 
time to BF are significant 
risk factors for prostate 
specific mortality
Time from surgery to BF (< or=3 
vs. >3years) significant risk factor 
for time to prostate cancer specific 
mortality
Denham et al. 2008 
Newcastle, Australia
802 TROG 96.01 trial
Locally advanced prostate 
cancer. 
RT alone or with short term 
ADT 3/6 months
Time to BF was better than 
PSADT at predicting the 
trial finding and satisfied all 
four Prentice criteria at cut-
offs <1.5, <2, <2.5 yrs
6 months ADT before and 
during RT beneficial
TTBF is a useful surrogate end-
point for prostate cancer specific 
mortality
Sandler et al. 2003 1551 RTOG 92-02
Short vs. long term ADT
T2c-4 prostate cancer
Analysis by Valicencti JCO 
2005;23:4549 showed that 
PSADT useful surrogate
The RTOG 92-02 trial 
supports the addition of LT 
adjuvant AD to STAD with 
RT for T2c-T4 PC. In the 
exploratory subset analysis 
of patients with Gleason 
scores 8 to 10, LT adjuvant 
AD resulted in a survival 
advantage
Time to treatment failure not a 
surrogate for prostate cancer spe-
cific mortality. Failed 4th Prentice 
criterion
Buyyounouski et al. 2008  
Fox Chase, Philadelphia
1174 T1C-T3Nx-N0M0
Prostate cancer patients 
treated with 3D conformal 
RT
211 patients had BF of 1174 Interval to BF <18 months, 
Gleason score7-10, PSA 
nadir >or=2ng/ml and 
decreasing RT dose were 
predictive of distant 
metastasis
On Cox proportional hazards 
modelling an interval to BF <18 
months was the only predictor of 
prostate cancer specific mortality 
(p=0.0003)
Table 5. Clinical studies relevant to EBF as a surrogate for disease specific mortality.
parameters (initial PSA, Gleason score and T-stage) with 
biochemical recurrence in the first two years post RT and NADT. 
Walz et al., (2009) devised a predictive nomogram of recurrent 
disease using Cox regression models of 2911 patients post RRP. 
They found that pathological Gleason sum 7 or greater, seminal 
vesicle invasion and lymph node involvement were the most 
powerful predictors of biochemical recurrence [22]. A further 
study of biochemical recurrence after radical prostatectomy 
found that Gleason grade and pathologic stage (p<0.002) 
were predictive of biochemical recurrence [23]. In our study, 
established predictive factors: initial PSA, Gleason score and 
T-stage were assessed to see if they were associated with EBF. 
We found that initial PSA, T-Stage group and Gleason score 
group predicted EBF. Compared to those with T1-T2b stage 
disease patients with T2c–T4 prostate cancer had a greater 
risk of EBF, after adjustment for initial PSA and Gleason score 
group. A study of similar design to the ICORG 97-01 was 
that of the Trans-Tasman Radiation Oncology Group (TROG) 
96.01 Trial [20]. That study of 802 men with locally advanced 
prostate cancer compared treating prostate cancer with RT 
alone to 3 or 6 months of maximum short-term ADT before 
and during RT. In a subsequent analysis they examined time 
to BF (TTBF) and PSADT as surrogate endpoints for PCSM. 
TTBF was found to be a useful vicarious endpoint, and more 
particularly TTBF in a cut point band from less than 1.5 to less 
than 2.5 years predicted the endpoints of the trial. All four 
Prentice surrogacy criteria [24] were satisfied using the less 
than 1.5, less than 2, and less than 2.5 year cut-offs.
The distinction between prognostic factors and those 
that predict response to therapy is also clinically important. 
Men with a PSA doubling time after radical prostatectomy 
of less than 6 months have a worse prognosis overall than 
those with a PSA doubling time of 6 months or longer, but 
they derive a greater benefit from salvage therapy relative to 
untreated patients [2]. This may indicate that many men with 
a PSA doubling time of 6 months or longer have biologically 
less aggressive disease that is less likely to result in metastatic 
disease or death during their lifetime. An analysis of the RTOG 
92-02 study of short versus long term ADT in T2c-4 prostate 
cancer found that time to treatment failure did not satisfy the 
4th Prentice criterion (i.e., that the surrogate mediates the 
effect of initial treatment on the true endpoint) [25,26]. That 
study was designed so that all patients received goserelin 
and flutamide for 4 months before and during RT and were 
then randomised to no further ADT or 24 months of goserelin. 
The postulated reason that the 4th Prentice criterion was not 
satisfied was that a proportion of patients on long term ADT 
that had recurrent disease were hormone insensitive at time 
of PSA relapse and therefore were insensitive to salvage ADT 
[27]. The TROG 96.01 study randomised patients to 0, 3 or 6 
months ADT before and during RT and the ICORG 97-01 study 
randomised to 4 versus 8 months NADT.
Because of the long natural history of prostate cancer, 
randomized trials designed to detect statistically significant 
differences in mortality often are prohibitive in terms of size, 
duration, and cost. The use of surrogate endpoints substantially 
decreases the size and duration of clinical trials, allowing 
more rapid prospective testing of hypotheses and potentially 
accelerating development of improved cancer treatment. 
Therefore an analysis of the natural history of EBF in this 
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context is even more important. Ultimately this study further 
supports the TROG 96.01 study that BF at or before 2 years 
post RT is associated with an increased risk of PCSM. Perhaps 
before these finding of time to biochemical failure and risk 
of PCSM are incorporated into routine practice a prospective 
clinical trial of time to biochemical failure and PCSM should be 
initiated. That study should obviate the inherent flaws in the 
clinically convenient but somewhat arbitrary selection of the 
2-year cut-off in the ICORG 97-01 supplementary analysis or 
the categorical cohort based approach in the TROG 96.01 study. 
A continuous model that discovers the optimal abscission 
time point and then extended actuarial documentation of 
the longitudinal PCSM outcomes are required.
Finally a previous Cochrane review did compare neo-
adjuvant hormone therapy with radiotherapy versus radio-
therapy alone for localized and locally advanced prostate cancer 
[28]. Outcome measures included biochemical free survival, 
and clinical disease free survival. Respective totals were 1.93 
[C.I. 1.45,2.56] and 1.86 [C.I. 1.43,2.40] favouring combined 
treatment. Ultimately only individualized patient data from 
other previous studies of neo-adjuvant hormonal therapy 
and radiotherapy will provide meaningful comparator data 
to out study and that of Denham in the Trans-Tasman study.
List of abbreviations 
ICORG: Irish Clinical Oncology Research Group
EBF: Early biochemical failure. Defined for the purposes of this study 
as biochemical relapse within 2 years of completion of 3D- conformal 
radiotherapy. 
The definition of biochemical (PSA) failure in the ICORG 97-01 trial 
protocol was in accordance with the American Society for Therapeutic 
Radiation and Oncology (ASTRO) consensus statement (A) but data 
was analyzed using the new definition of biochemical failure, defined 
as PSA >nadir after RT +2 ng/mL (B, C). 
A. American Society for Therapeutic Radiology and Oncology: 
Consensus Statement. Guidelines for PSA following radiation therapy. 
Int J Radiat Oncol Biol Phys 1997;37:1035–1041. 
B. Pickles T, Kim-Sing C, Morris WJ, et al., Evaluation of the Houston 
biochemical relapse definition in men treated with prolonged 
neo-adjuvant and adjuvant androgen ablation and assessment of 
follow-up lead-time bias. Int J Radiat Oncol Biol Phys 2003;57:11–18. 3. 
C. Roach M, Hanks G, Thames H, et al., Defining biochemical failure 
following radiotherapy with or without hormone therapy in men 
with clinically localized prostate cancer: Recommendations of the 
RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol 
Phys 2006; 65:965–974.
LBF: Late biochemical failure. Defined for the purposes of this study 
as biochemical relapse greater than 2 years post completion of 3D- 
conformal radiotherapy. As per the definitions A-C above.
A 2-year cut off was decided upon prior to data analysis as practical 
duration to assist the physician in the clinic.
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